Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are no...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
2016
|
| Online Access: | http://hdl.handle.net/20.500.11937/36646 |
| _version_ | 1848754828438667264 |
|---|---|
| author | Swamy, S. Kameshwar, V. Shubha, P. Looi, C. Shanmugam, M. Arfuso, Frank Dharmarajan, Arunasalam Sethi, Gautam Shivananju, N. Bishayee, A. |
| author_facet | Swamy, S. Kameshwar, V. Shubha, P. Looi, C. Shanmugam, M. Arfuso, Frank Dharmarajan, Arunasalam Sethi, Gautam Shivananju, N. Bishayee, A. |
| author_sort | Swamy, S. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotoxic molecules with significant side effects. Sorafenib, a multi-targeted tyrosine kinase inhibitor, is the only approved targeted drug for HCC patients. However, due to adverse side effects and limited efficacy, there is a need for the identification of novel pharmacological drugs beyond sorafenib. Several agents that target and inhibit various signaling pathways involved in HCC are currently being assessed for HCC treatment. In the present review article, we summarize the diverse signal transduction pathways responsible for initiation as well as progression of HCC and also the potential anticancer effects of selected targeted therapies that can be employed for HCC therapy. |
| first_indexed | 2025-11-14T08:46:37Z |
| format | Journal Article |
| id | curtin-20.500.11937-36646 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T08:46:37Z |
| publishDate | 2016 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-366462017-09-13T15:35:35Z Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma Swamy, S. Kameshwar, V. Shubha, P. Looi, C. Shanmugam, M. Arfuso, Frank Dharmarajan, Arunasalam Sethi, Gautam Shivananju, N. Bishayee, A. Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotoxic molecules with significant side effects. Sorafenib, a multi-targeted tyrosine kinase inhibitor, is the only approved targeted drug for HCC patients. However, due to adverse side effects and limited efficacy, there is a need for the identification of novel pharmacological drugs beyond sorafenib. Several agents that target and inhibit various signaling pathways involved in HCC are currently being assessed for HCC treatment. In the present review article, we summarize the diverse signal transduction pathways responsible for initiation as well as progression of HCC and also the potential anticancer effects of selected targeted therapies that can be employed for HCC therapy. 2016 Journal Article http://hdl.handle.net/20.500.11937/36646 10.1007/s11523-016-0452-7 restricted |
| spellingShingle | Swamy, S. Kameshwar, V. Shubha, P. Looi, C. Shanmugam, M. Arfuso, Frank Dharmarajan, Arunasalam Sethi, Gautam Shivananju, N. Bishayee, A. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma |
| title | Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma |
| title_full | Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma |
| title_fullStr | Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma |
| title_full_unstemmed | Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma |
| title_short | Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma |
| title_sort | targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma |
| url | http://hdl.handle.net/20.500.11937/36646 |